PDCD1 and neoplasm: The T cell-inflamed GEP score (5) is either an individual cross-tumor predictor or combined with other predefined biomarkers like TMB (16), for immunotherapy, especially in PD-1 blockade- or PD-L1-based combination therapy regimens.